Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
hiPSC-derived CAAR-T cell therapy
- Development stage
- Preclinical
- Lead developer
- ISAR Bioscience
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
hiPSC-derived CAAR-T cell therapy is an experimental cellular immunotherapy platform being developed by ISAR Bioscience. This technology utilizes human induced pluripotent stem cells (hiPSCs) to generate a standardized, scalable source of T-cells, which are then engineered with Chimeric Autoantibody Receptors (CAARs). Unlike traditional CAR-T cells that target surface antigens on cancer cells, CAAR-T cells are designed to express a specific autoantigen on their surface. This allows them to selectively recognize and eliminate B-cell clones that express autoantibodies (B-cell receptors) specific to that antigen. The primary goal is to treat autoimmune diseases, such as Graves' disease, endocrine orbitopathy, and rheumatoid arthritis, by depleting only the pathogenic B-cell populations responsible for the disease while sparing healthy B-cells and avoiding broad immunosuppression. The program is currently in preclinical development for both autoimmune conditions and cancer.
- Other names
- CAAR-T cell therapy (hiPSC-derived)hiPSC-derived CAAR-T cellshiPSC-derived CAR-T/CAAR-T cell therapy
02
Targets
BCR (Autoantigen-specific B-cell receptor)
Beyond the preview
Go deeper on hiPSC-derived CAAR-T cell therapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on hiPSC-derived CAAR-T cell therapy.